文献速递骨质疏松与钙磷/甲状旁腺

甲状旁腺腺瘤中GCM2沉默与启动子高甲基化及组蛋白3甲基化获得相关

GCM2 Silencing in Parathyroid Adenoma Is Associated With Promoter Hypermethylation and Gain of Methylation on Histone 3.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该研究探讨了散发性甲状旁腺腺瘤中GCM2转录的表观遗传改变及其与疾病指标的关系。在33例腺瘤和10例对照组织中,GCM2 mRNA和蛋白表达降低,与启动子高甲基化(P < .001)和H3K9me3水平升高(P < .04)相关。PTH-C1细胞中DAC处理可恢复GCM2表达并降低DNMT1蛋白,提示表观遗传调控参与腺瘤发生且DAC可能为治疗研究方向。

要点

  • 散发性甲状旁腺腺瘤中GCM2 mRNA和蛋白表达低于对照组织。
  • GCM2启动子高甲基化(P < .001)和H3K9me3升高(P < .04)与表达降低相关。
  • DAC处理PTH-C1细胞可增加GCM2转录并降低DNMT1蛋白。

核心结论

  • 甲状旁腺腺瘤中GCM2表达抑制与启动子高甲基化和H3K9me3升高同时相关。
  • DAC处理可在PTH-C1细胞中恢复GCM2表达。
  • 结果提示表观遗传景观可能参与甲状旁腺腺瘤的肿瘤发生,DAC可能是潜在治疗研究方向。

研究设计与样本

  • 研究分析了33例腺瘤和10例对照甲状旁腺组织。
  • 采用RT-qPCR和免疫组化检测GCM2 mRNA和蛋白表达。
  • 采用亚硫酸氢盐测序和染色质免疫沉淀-qPCR检测GCM2启动子DNA甲基化和组蛋白甲基化/乙酰化。
  • 在PTH-C1细胞中用5-aza-2'-脱氧胞苷(DAC)和BRD4770处理,评估GCM2 mRNA和DNMT1蛋白水平。

主要发现

  • 散发性腺瘤组织中GCM2 mRNA和蛋白表达低于对照甲状旁腺组织。
  • 腺瘤中GCM2启动子高甲基化(P < .001)和H3K9me3水平较高(P < .04)与GCM2表达降低相关。
  • PTH-C1细胞中DAC处理导致GCM2转录增加和DNMT1蛋白表达降低。
  • BRD4770处理细胞显示H3K9me3水平降低,但GCM2转录变化无统计学意义。

临床怎么用

  • GCM2启动子高甲基化和H3K9me3可作为理解甲状旁腺腺瘤表观遗传机制的线索。
  • DAC恢复GCM2表达的作用值得在甲状旁腺腺瘤治疗研究中进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Glial cells missing 2 (GCM2), a zinc finger-transcription factor, is essentially required for the development of the parathyroid glands. OBJECTIVE: We sought to identify whether the epigenetic alterations in GCM2 transcription are involved in the pathogenesis of sporadic parathyroid adenoma. In addition, we examined the association between promoter methylation and histone modifications with disease indices. METHODS: Messenger RNA (mRNA) and protein expression of GCM2 were analyzed by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry in 33 adenomatous and 10 control parathyroid tissues. DNA methylation and histone methylation/acetylation of the GCM2 promoter were measured by bisulfite sequencing and chromatin immunoprecipitation-qPCR. Additionally, we investigated the role of epigenetic modifications on GCM2 and DNA methyltransferase 1 (DNMT1) expression in parathyroid (PTH)-C1 cells by treating with 5-aza-2'-deoxycytidine (DAC) and BRD4770 and assessed for GCM2 mRNA and DNMT1 protein levels. RESULTS: mRNA and protein expression of GCM2 were lower in sporadic adenomatous than in control parathyroid tissues. This reduction correlated with hypermethylation (P < .001) and higher H3K9me3 levels in the GCM2 promoter (P < .04) in adenomas. In PTH-C1 cells, DAC treatment resulted in increased GCM2 transcription and decreased DNMT1 protein expression, while cells treated with the BRD4770 showed reduced H3K9me3 levels but a nonsignificant change in GCM2 transcription. CONCLUSION: These findings suggest the concurrent association of promoter hypermethylation and higher H3K9me3 with the repression of GCM2 expression in parathyroid adenomas. Treatment with DAC restored GCM2 expression in PTH-C1 cells. Our results showed a possible epigenetic landscape in the tumorigenesis of parathyroid adenoma and also that DAC may be a promising avenue of research for parathyroid adenoma therapeutics.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Singh P, Bhadada SK, Dahiya D, et al. GCM2 Silencing in Parathyroid Adenoma Is Associated With Promoter Hypermethylation and Gain of Methylation on Histone 3. J Clin Endocrinol Metab. 2021. PMID: 34077544. doi:10.1210/clinem/dgab374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。